Buy This Stock to Bet on Biogen Drug, Says Raymond James & Associates
(Bloomberg) -- Investors should buy Genworth Financial Inc. shares on the prospect that Biogen Idec Inc.’s experimental Alzheimer’s drug could reduce claims costs at the long-term care insurer, Raymond James & Associates Inc. said.
“Investors in Genworth are receiving a free option on the drug,” Steven Schwartz, an analyst at Raymond James, said in a note Monday. “About 50 percent of Genworth’s long-term care insurance claims payments are for Alzheimer’s or other forms of dementia.”
Help employers find you! Check out all the jobs and post your resume.
“Investors in Genworth are receiving a free option on the drug,” Steven Schwartz, an analyst at Raymond James, said in a note Monday. “About 50 percent of Genworth’s long-term care insurance claims payments are for Alzheimer’s or other forms of dementia.”
Help employers find you! Check out all the jobs and post your resume.